EOLS logo

Evolus, Inc.

EOLS
Healthcare|Drug Manufacturers - Specialty & Generic|US
$6.80
+0.01 (+0.15%)
DCF Value
$9.13
Cash / Share
$0.63
Next Earnings Report
Mar 2, 2027
EPS est. $0.10 · Revenue est. $98.9M
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Jun 5, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (1)

Mar 2027
Est. completion
P4Neck Muscle Issue
BoTox Into the Sternocleidomastoid Muscles (SCM)
NCT06903975n=30

Recent Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Nov 5, 2026 · PRNewsWire
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook
Nov 4, 2026 · Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Nov 3, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Oct 29, 2026 · PRNewsWire
Evolus to Participate in Upcoming Investor Conferences in New York and London
Oct 28, 2026 · Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Oct 27, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Oct 22, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Oct 20, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Oct 15, 2026 · PRNewsWire
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Oct 14, 2026 · Business Wire

SEC Filings (56)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Aug 31, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jul 8, 20268-KMaterial eventDocumentIndex
Jun 12, 2026EFFECTDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
Jun 5, 2026S-3Shelf registrationDocumentIndex
May 4, 202610-QQuarterly reportDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 29, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 29, 2026ARSAnnual report to holdersDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 13, 20268-KMaterial eventDocumentIndex
Mar 3, 2026S-8Employee stock planDocumentIndex
Mar 3, 202610-KAnnual reportDocumentIndex
Mar 3, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Sep 8, 20258-KMaterial eventDocumentIndex
Aug 18, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
Jun 6, 20258-KMaterial eventDocumentIndex
May 27, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex